Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
17 results
  • Melanoma, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Leukemia

26-113          Phase I

A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors

  • Melanoma, Lung Cancer, Head and Neck Cancer, Bladder Cancer

18-418          Phase III

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

  • Head and Neck Cancer, Melanoma

23-589          Phase I

A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors

  • Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Melanoma

22-173          Phase I

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects with Front-line Advanced NSCLC and Other Selected Indications

  • Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Prostate Cancer, Breast Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

  • Melanoma

24-262          Phase II

A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination with Anti-PD-1 in Advanced Solid Tumors

  • Endometrial Cancer, Melanoma, Pancreatic Cancer, Colorectal Cancer, Lung Cancer

26-098          Phase II

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

  • Melanoma

24-043          Phase III

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  • Pancreatic Cancer, Breast Cancer, Endometrial Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma

25-587          Phase II

A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors

Showing 1 - 10 of 17 results